Ball & Co Wealth Management’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
BBA
KCM
Ball & Co Wealth Management's SMMT Position: Q3 2026 in Review
Ball & Co Wealth Management sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 1,500 shares — an estimated $21K sold.
Ball & Co Wealth Management first reported a position in SMMT in Q2 2025 and held it in 4 quarters. The position peaked at $31K in Q2 2025. 294 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- Ball & Co Wealth Management reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
- Ball & Co Wealth Management sold 1,500 Summit Therapeutics shares in Q3 2026, an estimated $21K.
- Ball & Co Wealth Management first reported a position in Summit Therapeutics in Q2 2025 and held it in 4 quarters.
- Ball & Co Wealth Management's Summit Therapeutics position peaked at $31K in Q2 2025.
- 294 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on Ball & Co Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.